Blog

What are Primary Care Networks?

In summer 2019, the NHS announced major changes to the structure of GPs surgeries across the UK with the introduction of Primary Care Networks. These changes may have significant impact on how pharma companies interact with key PCN personnel. Learn how Inspiremed can help.

In summer 2019, the NHS announced that it was bringing the UK’s general practices together to work ‘at scale’ in Primary Care Networks (PCNs). The reason?

“Many people are living with long term conditions such as diabetes and heart disease, or suffer with mental health issues and may need to access their local health services more often. To meet these needs, practices have begun working together and with community, mental health, social care, pharmacy, hospital and voluntary services in their local areas in primary care networks.”
(NHS England)

The new PCNs form around 1,300 geographical networks and cover populations of approximately 30–50,000 patients. The smaller networks of 30,000 patients are usually those found in very rural areas. Their aim? To promote ‘integrated care.’ (BMA)

The King’s Fund reports that the reasons behind the change include improving the ability of practices to:

  • recruit and retain staff
  • manage financial and estates pressures
  • provide a wider range of services to patients
  • more easily integrate with the wider health and care system

Since the NHS announcement, all but a handful of GP practices in England have come together and in January 2020, the Guardian reported, “About 1,250 PCNs are due to start work in England in April. Each will include a number of local surgeries and cover populations of 30,000-50,000.”

The BMA reports that, “The main aim of PCNs is to focus services around local communities and help rebuild and reconnect the primary healthcare team across the area they cover through the network, providing workload support for practices at the same time.” (BMA)

The 3-minute animation on this page (click here) provides a clear explanation of the new arrangements, and how general practices have begun working together and with community, mental health, social care, pharmacy, hospital and voluntary services in their local areas in primary care networks.

How can Inspiremed help pharma?

Mapping practice’s within the new PCNs into market access analytics and segmentation models gives direct insight into how these groups are structured across CCGs and identifies the key stakeholders.

Our analytics can quickly help you with market access dynamics for this important and evolving NHS group.

Get in touch to find out more.

Contact us 01600 891594 or email info@inspire-med.co.uk 

“I am extremely happy with the model and with the working relationship we have with Inspiremed.”

Country Manager UK, Leading Diagnostics Company

“Our sales team use RX Analyser to analyse results and opportunity; it’s used by management to measure performance and identify national trends to drive targeting and strategy.”

National Sales Manager, UK Pharmaceutical Company

“Data drives our activity in marketing and sales and Rx Analyser is the perfect tool for this.”

Sales and Marketing Manager, Leading Healthcare Company, 2016

“I recommend Rx Analyser. The product is a combination of software and service; the software is easy to use and quick to train, Inspiremed provide a high level of service in terms of data support and support.”

National Sales Manager, UK Pharmaceutical Company

“Working with Inspiremed is a great partnership experience and they make sure they understand your business, the industry that you are in and what you want to achieve in the use of the product.”

National Sales Manager, UK Pharmaceutical Company

“I use the data from RXA Budget Impact Model daily. It is the core of everything we do! I cannot recommend the model more. It has had a substantial impact on our business across the board and I would not be without it.”

Country Manager UK, Leading Diagnostics Company

Sign up for added insights